| Project/Area Number |
22650238
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | 公益財団法人がん研究会 (2011)
Japanese Foundation For Cancer Research (2010) |
|---|
Principal Investigator |
FUJITA Naoya 公益財団法人がん研究会, がん化学療法センター基礎研究部, 部長 (20280951)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,470,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2010: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | Pimキナーゼ / 結晶構造解析 / 阻害剤 / p27^<Kip1> / がん / 生体分子 / シグナル / Pim |
|---|
| Research Abstract |
The serine/threonine kinase Pim-1 plays an important role in cell cycle progression and apoptosis inhibition, resulting in prostate tumorigenesis. Therefore, Pim-1 inhibition has been expected to be an attractive target for developing new anti-cancer drugs. However, no small compounds targeting Pim-1 have progressed to clinical use because of their lack of specificity. Here we analyzed the X-ray crystal structure of Pim-1 in complex with p27^<Kip1> peptide at 1.6 A resolution. Adding eight tandem Arg residues, R8, we generated a new cell-permeable Pim-1-inhibitory p27^<Kip1> peptide that could interfere with the binding of Pim-1 to its substrates and act as an anti-cancer drug. Treatment of prostate cancer DU145 with the peptide induces G1 arrest and subsequently apoptosis in vitro. The peptide could also inhibit tumor growth in in vivo prostate cancer xenograft models.
|
